Zhang Minjie, Lou Pengqiang, Shou Dan, Tong Peijian, Zhang Yang
School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, China.
Institute of Orthopaedics and Traumatology, The First Affliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Traditional Chinese Medicine), Hangzhou, China.
Gerontology. 2025;71(3):221-238. doi: 10.1159/000543386. Epub 2025 Feb 12.
BACKGROUND: Orthopedic diseases, including osteoarthritis, osteoporosis, and age-related musculoskeletal disorders, significantly impact quality of life and are becoming increasingly prevalent with aging populations. A growing body of evidence highlights the role of cellular senescence in the pathogenesis of these conditions. Senescent cells (SCs), characterized by irreversible cell cycle arrest, accumulate in tissues over time, contributing to inflammation, tissue degeneration, and impaired regeneration. The emerging field of senolytics, which aims to selectively eliminate these SCs, has garnered attention as a novel therapeutic strategy in orthopedics. SUMMARY: Senolytic drugs, including small molecules, peptides, and natural compounds, have shown promise in preclinical models and early clinical trials for the treatment of various age-related diseases. In orthopedics, senolytics have been investigated for their potential to ameliorate cartilage degradation, bone fragility, and other degenerative changes associated with aging. Recent studies have demonstrated that targeting SCs in musculoskeletal tissues can improve tissue function, reduce inflammation, and promote regeneration. Although the majority of research is still in the preclinical phase, the positive outcomes from animal studies and early clinical trials suggest that senolytic drugs may offer new therapeutic avenues for orthopedic diseases. KEY MESSAGES: Senolytic therapies hold significant potential for treating orthopedic diseases by targeting the underlying cellular senescence that contributes to tissue degeneration and inflammation. Preclinical and clinical studies indicate that senolytic drugs may enhance tissue repair, alleviate symptoms, and slow disease progression in musculoskeletal disorders. Further research is needed to optimize drug efficacy, ensure safety, and identify patient populations that may benefit the most from these treatments. The development of senolytic drugs could revolutionize the management of aging-related orthopedic diseases, providing a more targeted and effective approach than current treatments.
背景:骨科疾病,包括骨关节炎、骨质疏松症和与年龄相关的肌肉骨骼疾病,对生活质量有重大影响,并且随着人口老龄化日益普遍。越来越多的证据突出了细胞衰老在这些病症发病机制中的作用。衰老细胞(SCs)的特征是不可逆的细胞周期停滞,随着时间的推移在组织中积累,导致炎症、组织退化和再生受损。衰老细胞溶解剂这一新兴领域旨在选择性地消除这些衰老细胞,作为骨科的一种新型治疗策略已受到关注。 总结:衰老细胞溶解药物,包括小分子、肽和天然化合物,在治疗各种与年龄相关疾病的临床前模型和早期临床试验中已显示出前景。在骨科领域,已对衰老细胞溶解剂改善软骨退化、骨脆性以及与衰老相关的其他退行性变化的潜力进行了研究。最近的研究表明,针对肌肉骨骼组织中的衰老细胞可以改善组织功能、减轻炎症并促进再生。尽管大多数研究仍处于临床前阶段,但动物研究和早期临床试验的积极结果表明,衰老细胞溶解药物可能为骨科疾病提供新的治疗途径。 关键信息:衰老细胞溶解疗法通过靶向导致组织退化和炎症的潜在细胞衰老,在治疗骨科疾病方面具有巨大潜力。临床前和临床研究表明,衰老细胞溶解药物可能增强组织修复、缓解症状并减缓肌肉骨骼疾病的疾病进展。需要进一步研究以优化药物疗效、确保安全性并确定可能从这些治疗中获益最大的患者群体。衰老细胞溶解药物的开发可能会彻底改变与衰老相关的骨科疾病的管理,提供一种比当前治疗更具针对性和有效性的方法。
Biomater Sci. 2025-6-25
Cochrane Database Syst Rev. 2021-4-19
Cochrane Database Syst Rev. 2018-2-6
Cochrane Database Syst Rev. 2017-12-22
Cochrane Database Syst Rev. 2008-7-16
J Prev Alzheimers Dis. 2023
Health Technol Assess. 2024-10